Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Citramon-Darnitsa
- Development stage
- Unknown
- Lead developer
- Darnitsa
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Citramon-Darnitsa is a fixed-dose combination analgesic, antipyretic, and anti-inflammatory medication developed and manufactured by Darnitsa Pharmaceuticals. It is composed of three active ingredients: acetylsalicylic acid (aspirin), paracetamol (acetaminophen), and caffeine. The mechanism of action is multi-modal: acetylsalicylic acid and paracetamol inhibit cyclooxygenase (COX) enzymes, thereby reducing the synthesis of prostaglandins responsible for pain and inflammation. Caffeine acts as an adenosine receptor antagonist, which not only provides a mild stimulant effect but also potentiates the analgesic efficacy of the other components by improving their absorption and modulating central pain pathways. It is widely used for the symptomatic relief of headache, migraine, dental pain, muscle pain, and fever.
- Brand names
- Citramon-DarnitsaCitramone-DarnytsyaЦитрамон-Дарниця
- Other names
- CitramonCitramone
02
Targets
PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)ADORA2A (Adenosine A₂A Receptor)ADORA1 (Adenosine receptor A1 subtype)
Beyond the preview
Go deeper on Citramon-Darnitsa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Citramon-Darnitsa.